– CANADA, Brossard – Diagnos Inc. (TSX: ADK | OTC: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence, today announced the appointments of Vincent Duhamel and Robert Dunn to its board of directors.
“We are pleased that Vincent and Robert have accepted to join the Board. I am convinced that their vast work experience and business relationships will directly contribute to the growth and success of our business,” said President, André Larente.
The Corporation also announced the resignation of Georges Hébert from his position as director and chairman of the audit committee. The Board wishes to thank Mr. Hébert for his contribution to the development of DIAGNOS.
About Vincent Duhamel
Mr. Duhamel has an established track record in overseeing start-up companies and restructuring operations, as well as leading large investment teams in multi-cultural environments. Mr. Duhamel is Vice Chairman of the board of directors of Fiera Capital, a leading independent global asset management firm. Prior to joining Fiera Capital, he held several senior positions in Asia and Canada. Mr. Duhamel has played an active role on several boards and committees, including at the CFA Institute and the Stock Exchange of Hong Kong.
About Robert Dunn
With 40 years of extensive experience in the insurance business, Mr. Dunn brings expertise in, among others, the financial and communications sectors. From 2017 to 2019, Mr. Dunn held the position of Vice-Chairman and Executive Vice President of HUB International Québec Ltd.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence tool CARA. CARA is a teleophthalmology platform that integrates with existing equipment and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
For more information: http://www.diagnos.ca/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.